RLY-2608

CAS No. 2733573-94-7

RLY-2608( —— )

Catalog No. M37293 CAS No. 2733573-94-7

RLY-2608 is a selective mutant PI3Kα inhibitor that inhibits tumor growth in a PIK3CA mutant xenograft model.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
2MG 818 In Stock
5MG 1017 In Stock
10MG 1644 In Stock
25MG 2374 In Stock
50MG 3202 In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    RLY-2608
  • Note
    Research use only, not for human use.
  • Brief Description
    RLY-2608 is a selective mutant PI3Kα inhibitor that inhibits tumor growth in a PIK3CA mutant xenograft model.
  • Description
    RLY-2608 is a first-in-class allosteric mutant-selective inhibitor of PI3Ka.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    PI3K/Akt/mTOR signaling
  • Target
    PI3K
  • Recptor
    PI3K
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    2733573-94-7
  • Formula Weight
    608.91
  • Molecular Formula
    C29H14ClF5N6O2
  • Purity
    >98% (HPLC)
  • Solubility
    ——
  • SMILES
    N(C(=O)C1=CC(C(F)(F)F)=CC(F)=C1)C2=C3[C@@H](NC(=O)C3=CC(=C2)C4=C(C#N)N5C(C=C4)=NC=N5)C6=C(Cl)C=CC(F)=C6
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Andreas Varkaris, et al. Discovery and clinical proof-of-concept of RLY-2608, a first-in-class mutant-selective allosteric PI3Ka inhibitor that decouples anti-tumor activity from hyperinsulinemia. Cancer Discov. 2023 Nov 2.?
molnova catalog
related products
  • NSC5844

    NSC5844 (RE640) is a bisquinoline compound with C-C chemokine receptor type 1 (CCR1)-agonistic activities.

  • IHMT-PI3Kδ-372 S-iso...

    IHMT-PI3Kδ-372 S-isomer is a potent and selective PI3Kδ inhibitor with an IC50 of 14 nM. IHMT-PI3Kδ-372 S-isomer shows high selectivity over other class I PI3Ks (56~83 fold) and other protein kinases.

  • B591

    B591 (B-591) is a potent, specific pan-PI3K inhibitor with IC50 of 1.3/0.36/1.1/1.58 uM for PI3Kα/β/γ/δ, respectively.